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Abstract
Background: Resistance to chemotherapy remains one of the principle obstacles to the treatment of colon cancer.
In order to identify the molecular mechanism of this resistance, we investigated the role of the steroid and
xenobiotic receptor (SXR) in the induction of drug resistance. Indeed, this nuclear receptor plays an important role
in response to xenobiotics through the upregulation of detoxification genes. Following drug treatments, SXR is
activated and interacts with the retinoid X receptor (RXR) to induce expression of some genes involved in drug
metabolism such as phase I enzyme (like CYP), phase II enzymes (like UGT) and transporters (e.g. MDR1).
Results: In this study, we have shown that endogenous SXR is activated in response to SN-38, the active
metabolite of the anticancer drug irinotecan, in human colon cancer cell lines. We have found that endogenous
SXR translocates into the nucleus and associates with RXR upon SN-38 treatment. Using ChIP, we have
demonstrated that endogenous SXR, following its activation, binds to the native promoter of the CYP3A4 gene to
induce its expression. RNA interference experiments confirmed SXR involvement in CYP3A4 overexpression and
permitted us to identify CYP3A5 and MRP2 transporter as SXR target genes. As a consequence, cells overexpressing
SXR were found to be less sensitive to irinotecan treatment.
Conclusions: Altogether, these results suggest that the SXR pathway is involved in colon cancer irinotecan
resistance in colon cancer cell line via the upregulation of select detoxification genes.
Background
One of the challenges in cancer treatment is to under-
stand why some tumors fail to respond to chemotherapy.
Delineating in advance the subsets of tumors presenting
treatment failure and identifying which pathways are
involved in drug resistance would thus represent a signif-
icant advance. Several factors contribute to the develop-
ment of drug resistance. Inadequate drug access to the
tumor, drug metabolism and excretion, activation of
DNA repair mechanisms, and inactivation of cell death
pathways have all been proposed as potential mechan-
isms used by tumor cells to escape treatment [1,2].
Drug metabolism reactions are divided into three
phases: functionalization (phase I enzyme), conjugation
(phase II enzymes), and transport (phase III proteins),
but it is essentially carried out by cytochrome p450 3A4
(CYP3A4), which metabolizes more than 50% of all
administered drug [3]. CYP3A4 is the predominant iso-
form of monooxygenases present in the liver but there
is also evidence that metabolism occurs within the
tumors that express this isoform, and thereby reduces
the efficacy of chemotherapeutic agents [4,5]. It has
been demonstrated that the transcriptional regulation of
the CYP3A4 gene was mediated by the steroid and
xenobiotic receptor SXR, also known as the nuclear
receptor PXR (pregnane X receptor) [6-9]. SXR is a
nuclear receptor mainly expressed in intestine and liver
[9]. Following its activation by xenobiotics such as
rifampicin, SXR interacts with the retinoid X receptor
(RXR) to induce the transcriptional activation of several
genes involved in drug metabolism [6,9]. In humans,
SXR has been reported to bind the promoter and
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CYP2B and CYP2C) [7,9-15], the UDP-glucuronosyl-
transferase 1A1 (UGT1A1) [16], as well as the xenobio-
tic transporters multidrug resistance 1 (MDR1) and
organic anion transporter 2 [17,18]. For these reasons,
SXR is believed to play an important role in the defense
against drugs by upregulating the expression of detoxifi-
cation genes.
Irinotecan (or CPT-11), a camptothecin derivative, is one
of the major drugs used in the treatment of colorectal can-
cers [19]. Irinotecan is a prodrug that forms the pharmaco-
logically active compound 7-ethyl-10-hydroxycampto-
thecin (or SN-38) via carboxylesterases 1 and 2 (CE1, CE2),
but mostly by CE2 [20]. This agent then interacts with
DNA topoisomerase I to induce the formation of cleavage
complexes that prevent DNA replication. The collision of
trapped topoisomerases with DNA replication forks
induces DNA double strand breaks that finally lead to cell
cycle arrest and cell death [21]. Irinotecan undergoes
extensive metabolism: in both the liver and the intestine, it
is converted to inactive metabolites by CYP3A4 and
CYP3A5 [5,22] while its derivative SN-38 is inactivated
through glucuronidation via UGT1A1, UGT1A6, UGT1A7
or UGT1A9 [23]. Irinotecan and its metabolites are also
subject to detoxification by different export pumps like
MDR1, breast cancer resistance protein (BCRP) and multi-
drug resistance proteins 1 and 2 (MRP1, MRP2) [24-28].
Since CYP3A4 upregulation is an important mechanism of
drug resistance, these observations suggest that the SXR
transcription factor could play an important role in tumor
escape to irinotecan treatment through the upregulation of
CYP3A4 and drug detoxification.
In this study, we identified SN-38, the active metabo-
lite of irinotecan, as a new activator of SXR and eluci-
dated a molecular mechanism by which colon cancer
cells might acquire resistance. Upon drug treatment of
colon cancer cell lines, SXR is translocated into the
nucleus and interacts with RXR. Then, the SXR/RXR
heterodimer binds to the promoter of the CYP3A4 gene
to induce its expression. As a consequence, cells overex-
pressing the SXR transcription factor appear to be sig-
nificantly less sensitive to irinotecan, perhaps due to an
enhanced expression of CYP3A4 leading to irinotecan
inactivation.
Altogether, these results reveal a complex network of
interactions indicating that the SXR pathway induces
the expression of detoxification genes in response to the
topoisomerase I inhibitor, thereby leading to enhance
drug resistance.
Results
SXR is recruited to the nucleus after SN-38 treatment
In order to determine if SXR is activated by CPT-11, or
i t sa c t i v ed e r i v a t i v eS N - 3 8 ,w eh a v es t u d i e dc e l l u l a r
localization of the endogenous nuclear receptor SXR
during CPT-11 and SN-38 treatment. Since it has been
previously reported that rifampicin stimulates SXR-
mediated transcription [6,9], this drug was used as a
positive control in our cell lines. Following stimulation,
cytoplasmic and nuclear extracts were recovered from
the colon cancer cell line LS180, used as drug target cell
model, and the hepatic cancer cell line HepG2, used as
the major site for irinotecan metabolism. Western blot
experiments were then performed with antibodies direc-
ted against SXR, the nucleus marker histone H3 and the
cytoplasmic marker a-tubulin (Figure 1A and 1D). Before
drug treatment, SXR was mainly cytoplasmic in LS180
cells and equally distributed between the cytosolic and
nuclear compartments in HepG2 cells. We observed that
rifampicin activated SXR by inducing its nuclear translo-
cation after a 2 h stimulation in both cell lines. Interest-
ingly, western blot experiments showed that SN-38 also
induced the nuclear translocation of SXR, which was cor-
related with decreased cytosolic content (Figure 1A).
Despite nuclear recruitment being observed in both cell
lines after SN-38 and rifampicin treatment, it was stron-
ger in the colon cell line. SXR nuclear recruitment was
confirmed by confocal microscopy experiment in LS180
cells after 4 h exposure to SN-38 (Figure 1B). In order to
determine if the SXR activation was an indirect conse-
quence of cell cycle arrest, we performed cell cycle analy-
sis by flow cytometry in LS180 treated with SN-38
(Figure 1C). Cell cycle arrest was not observed until 8 h
drug exposure, indicating that it was not a cause of SXR
activation. Moreover, SXR expression was not induced
after 4 h drug exposure, as observed by WB in figure 2,
meaning that the increase of SXR level in the nucleus
was not due to its overexpress i o n .N os i g n i f i c a n tv a r i a -
tion in SXR localisation was noticed after 8 h exposure to
CPT-11 (Figure 1D).
Thus, we concluded that SN-38 but not CPT-11
induced SXR nuclear recruitment in colon and hepatic
cell lines.
SXR interacts with the retinoid X receptor after SN-38
treatment
SXR belongs to the same subfamily of nuclear receptors
as thyroid hormone receptors (TRs) and retinoic acid
receptors (RARs) which form heterodimers with RXR to
mediate ligand-dependent transcription [29]. To deter-
mine if the nuclear translocation of SXR upon genotoxic
treatment induced its association with RXR, LS180 and
HepG2 cells were stimulated with 10 μM rifampicin, 10
ng/ml SN-38 and 1 μg/ml CPT-11 during 4 h. Coimmu-
noprecipitations were performed with anti-SXR antibody
and the proteins present in the immunoprecipitates
were revealed by immunoblotting with the RXR anti-
body (Figure 2). As expected, endogenous SXR and RXR
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Figure 1 SXR accumulates in the nucleus after SN-38 treatment. A. LS180 and HepG2 cells were treated with 10 μMr i f a m p i c i n( r i f )o r1 0
ng/ml SN-38 for the indicated times, then nuclear and cytoplasmic extracts were prepared and subjected to WB with the indicated antibodies.
B. After for 4 h exposure to 10 ng/ml SN-38, immunofluorescence experiment were performed in LS180 cells, showing SXR (green) and nucleus
(red). Yellow colour indicates colocalization. C. Analysis of the cell cycle was performed by flow cytometry in LS180 cells after SN-38 exposure. D.
LS180 and HepG2 cells were treated with 1 μM CPT-11 then nuclear and cytoplasmic extracts were prepared and subjected to WB as above.
Figure 2 SXR interacts with RXR in cells in a SN-38-dependent manner. LS180 and HepG2 cells were treated with 10 μM rifampicin (RIF), 10
ng/ml SN-38 (SN) or 1 μg/ml CPT-11 (CPT) for 4 h. Cell extracts were immunoprecipitated (IP) with either IgG (IP control) or anti-SXR (IP SXR) in
the presence of vehicle (ctl), rifampicin, SN-38 or CPT-11. Association of the endogenous RXR with the anti-SXR precipitate was detected by WB
using anti-RXR antibody. Input indicates endogenous RXR present in 5% of total cell lysates used in each IP. To ensure equal amounts were
precipitated, WB using anti-SXR was also performed.
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Page 3 of 12were found to co-immunoprecipitate following 4 h of
rifampicin stimulation. Interestingly, the same associa-
tion was also observed after 4 h of SN-38 treatment.
This interaction was dependent on the presence of the
drugs since a very weak interaction was detected
between the two proteins in non-stimulated cells. No
interaction between SXR and RXR was observed after 4
h of CPT-11 exposure in both cell lines (Figure 2).
We infer from these results that SXR interacted with
RXR upon SN-38 treatment in LS180 and HepG2 cells
whereas no interaction has been reported after CPT-11
treatment.
SXR interacts with the native cytochrome p450 3A4
promoter after SN-38 treatment
The formation of heterodimers between SXR and RXR
is expected to mediate DNA binding to xenobiotic-
response elements (XREs) present on SXR target genes
such as CYP3A4. To verify this observation, we deter-
mined by chromatin immunoprecipitation (ChIP)
experiments whether SN-38 treatment induced the
binding of the transcription factor to one of its target
genes, namely the CYP3A4 promoter. Two XREs were
previously found at the -7773/-7719 and -169/-150
regions of the promoter and were named binding site 1
and 2 respectively (Figure 3A). Previous studies had
shown that the two SXR binding sites worked in a
synergistic way but could induce CYP3A4 transcription
separately. Nevertheless, the binding site 2 was necessary
to the maximal activation [7,9].
Chromatin was prepared using a formaldehyde cross-
linking protocol and occupancy of the promoter was ana-
lyzed using specific pairs of primers spanning the two
XREs. As controls, PCR analysis was also performed with
a third set of primers spanning a promoter unrelated
region (Figure 3A), and immunoprecipitations were con-
ducted with irrelevant IgG to ensure the specificity of the
reaction. As expected, antibodies directed against SXR
precipitated DNA encompassing the two SXR responsive
elements of the CYP3A4 promoter following rifampicin
stimulation. Importantly, we also observed that SXR was
recruited to both XREs upon SN-38 treatment but not
upon CPT-11 treatment (Figure 3B). As a control, PCR
analysis did not detect any occupancy of the control
region located on the CYP3A4 promoter. Quantitative
PCR analysis indicated that SXR bound with the same
affinity to the two XREs (Figure 3C).
Increased binding of the transcription factor is
expected to facilitate the recruitment of the RNA poly-
merase II to the CYP3A4 promoter. To test this hypoth-
esis, ChIP experiments were also performed using
antibodies directed against the RNA polymerase II and
its active phosphorylated form. As expected, quantitative
PCR analysis indicated that the total RNA polymerase II
as well as the phosphorylated form were recruited to the
both SXR binding sites on CYP3A4 promoter after SN-
38 stimulation. Similar results were obtained by using
primers spanning the transcription start site (data not
shown). The binding of RNA polymerase was detected
on both XREs, suggesting that the recruitment of SXR
could induce cooperative DNA binding and the forma-
tion of a functional enhanceosome.
Altogether, these results indicate that the SXR tran-
scription factor bound to the native promoter of the
CYP3A4 gene in association with the activated RNA
polymerase II upon SN-38 treatment, but not upon
CPT-11 treatment.
SXR is involved in the SN-38-mediated upregulation of
select irinotecan detoxification genes
To extend our results, we investigated the role of SXR
in regulation of the genes involved in irinotecan meta-
bolism. We first identified by RT-qPCR which detoxifi-
cation genes were upregulated after CPT-11 and SN-38
treatment and then, after SXR expression inhibition, we
determined which of the upregulated genes were
induced by activation of the nuclear receptor.
To this end, LS180 and HepG2 cells were treated during
24 h with CPT-11 and SN-38. Quantitative PCR experi-
ments were then performed to detect the mRNA expres-
sion of the irinotecan metabolism phase I genes (CYP3A4,
CYP3A5), the main irinotecan metabolism phase II genes
(UGT1A1, UGT1A7) and the irinotecan transporters
genes (MDR1, MRP1, MRP2 and BCRP). As presented in
figure 4, in LS180 cells, SN-38 induces a strong increase in
CYP3A4 and CYP3A5 transcription (respectively 6 and 13
times) and a weaker effect was observed for UGT1A1,
UGT1A7 and MRP2 (~2-3 times) while CPT-11 treatment
has no effect. In HepG2 cells, upon SN-38 treatment,
CYP3A4, CYP3A5, MDR1 and BCRP mRNA were
i n c r e a s e d4t i m e s ,U G T 1 A 16t i m e sa n dM R P 1t w of o l d ,
whereas only UGT1A1 and BCRP genes were upregulated
(~2-3 times) after CPT-11 treatment.
W et h e ni n v e s t i g a t e dt h er o l eo fS X Ro nt h eC P T - 1 1
and SN-38-mediated upregulated genes. To this end,
LS180 and HepG2 cells were transiently transfected with
control siRNA or siRNA targeting SXR prior to stimula-
tion. As shown in figure 5A, siRNA transfection resulted
in a significant reduction in SXR levels in LS180 cells
(79% protein inhibition, measured by densitometry and
relative to GAPDH expression) and a weaker reduction
in HepG2 (55% inhibition). Interestingly, in LS180 cells,
SXR knockdown led to a 50% decrease of MDR1 and
MRP1 basal expression (Figure 5B). No significant effect
of SXR downregulation was noticed on the basal expres-
sion of all the genes tested in HepG2. Moreover, reduc-
tion of SXR levels by siRNA prevented the upregulation
of CYP3A4 and CYP3A5 following SN-38 treatment in
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Page 4 of 12LS180 (Figure 5C). The other tested genes showed no
appreciable expression change after SXR downregulation
(data not shown). In HepG2 cells, we observed that SXR
knockdown blunted the SN-38-induced expression of
most of the genes involved in irinotecan metabolism (Fig-
ure 5C). In addition, SXR downregulation had no effect
on CPT-11-induced gene expression (data not shown).
Altogether, these results indicate that the SXR tran-
scription factor activated the expression of the CYP3A4
and CYP3A5 gene in response to SN-38 in HepG2 and
LS180 cells. MDR1 and MRP1 expression also appeared
to be regulated by SXR in both cell lines while UGT1A1
and BCRP gene were regulated in a cell dependent
manner.
SXR promotes CPT-11 resistance in some colon cancer
cell lines
Since it is CPT-11 and not SN-38 which is converted to
inactive metabolites through CYP3A4 and CYP3A5, the
SXR-mediated upregulation of these genes should prevent
the effect of CPT-11 on cell death. As a consequence, cells
overexpressing SXR should be less sensitive to the topoi-
somerase inhibitor. To test this hypothesis, LS180 cells
and HCT116 cells, another colon cancer cell line which
not express SXR, were transiently transfected with SXR or
control expression vectors for 24 h, then treated with
increasing concentrations of irinotecan for 72 h (Figure 6).
We first verified that the cells expressed the CE2 needed
for CPT-11 conversion to the SXR activator SN-38 (Figure
6A). Then, the cytotoxicity assays confirmed that CPT-11
induced a dose-dependent decrease of cell survival in con-
trol conditions and that overexpression of SXR signifi-
cantly reduced irinotecan induced cell death in LS180 cells
(Figure 6B), as well as in HCT116 cells (Figure 6C).
Altogether, these results suggest that SXR overexpres-
sion limited the effect of CPT-11 on colon cancer cell
death.
Discussion
In addition to the regulation of tumor suppressor net-
works and DNA repair pathways, the ability of cancer
cells to survive genotoxic treatments also relies on the
Figure 3 SN-38 treatment induces binding of endogenous SXR to the native CYP3A4 promoter. A. ChIP assays were performed and DNA
was further analyzed either by classical PCR or by semi-quantitative PCR using a primer set specific for the promoter or control region as
indicated by the arrows on the schematic diagram of the CYP3A4 promoter. B. LS180 were treated with 10 μM of rifampicin (rif), 1 μg/ml CPT-11
or 10 ng/ml SN-38 for 4 h and subjected to formaldehyde cross-linking. Soluble chromatin was prepared by sonication. Precleared chromatin
solution was immunoprecipitated by antibodies anti-SXR or Ig control, and precipitated. PCR was performed with the precipitated DNA (IP SXR)
or the DNA present in 10% of total cell lysates used for each IP (input). C. Cells were treated with SN-38 for 4 h and subjected to ChIP as
described above with anti-SXR, anti-RNA phospho-ARN polymerase II and anti-RNA polymerase II. Enrichment factors were determined by qPCR
using GAPDH as threshold indicator (internal control for each IP).
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Page 5 of 12efficacy of their detoxification pathways. In this study,
we show for the first time that the nuclear receptor SXR
is activated by SN-38, the active derivative of irinotecan,
whereas CPT-11 itself is a very weak activator. Upon
SN-38 treatment, endogenous SXR translocates into the
nucleus, interacts with RXR and the so-formed heterodi-
mer binds the CYP3A4 promoter, allowing the recruit-
ment of the RNA polymerase and the expression of the
CYP3A4 gene. These molecular mechanisms operate in
colon cancer cells, a target of irinotecan treatment as
well as in liver cancer cells, a major site of irinotecan
metabolism.
Moreover, we show that LS180 colon cancer cells that
overexpress SXR are less sensitive to CPT-11 treatment
compared to control cells, indicating that this transcrip-
tion factor is involved in drug resistance, probably
through CYP3A4, CYP3A5, MDR1 and MRP1 upregula-
tion. In light of these observations, we propose a feed-
back model (Figure 7) in which the SXR-CYP3A
pathway is induced in response to irinotecan treatment
in colon cancer cells, SXR mediated expression of
detoxification genes allowing for drug resistance and
tumor escape to genotoxic treatments.
We observe some differences between the LS180 and
HepG2 cellular models. Indeed, expression analyses of
irinotecan detoxification genes (CYP3A, UGT1A and
ABC transporters) show that most of these genes are
induced upon SN-38 treatment, but their expression
pattern varies depending on cell type. Furthermore, we
find that HepG2 cells are more resistant to treatment:
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Figure 4 Induction of irinotecan metabolism genes after CPT-
11 and SN-38 treatment. LS180 and HepG2 cells were treated
with 1 μg/ml CPT-11 or 10 ng/ml SN-38 for 24 h and quantitative
RT-PCR were performed on irinotecan metabolism genes. Fold
inductions were calculated relative to the mean expression of
GAPDH and experiments were performed in triplicate. (
a ND for not
detected).
Figure 5 SXR involvement in induction of irinotecan metabolism genes. A. Detection of SXR by western blot in LS180 and HepG2 cells
after 48 h siRNA transfection. B. After 48 h siRNA transfection, cells were cultivated for 24 h in new medium and mRNA levels of the irinotecan
metabolism genes were determined. Data represent percentage of mRNA levels after siRNA-SXR transfection compared to siRNA-control
transfection. C. After 48 h siRNA transfection, cells were stimulated with 10 ng/ml SN-38 for 24 h and mRNA levels were determined. Data
represent fold induction of mRNA levels compared to untreated cells.
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Page 6 of 12after 72 h incubation, IC50 values are 3.7-fold higher for
CPT-11 and 5-fold higher for SN-38 in HepG2 than in
LS180 cells (data not shown). This discrepancy can be
explained by the upregulation of a large number of
detoxification genes in the hepatic model, leading to
stronger drug inactivation.
Moreover, SXR knockdown blunted but not abrogated
the increase of the select genes that were induced by
SN-38 treatment. We can hypothesize that the gene
transcription could be induced by other transcription
factors in addition to SXR. Thereby, the absence of SXR
could allow other constitutively active nuclear receptors
to access SXR target gene promoters. For example, it
has been demonstrated that CAR and SXR can be acti-
vated by some common ligands and induce the same
genes (CYP3A and CYP2B) by using the same consensus
sites [30]. Other studies have established that FXR and
VDR could share some target gene binding sites with
SXR (reviewed by Zhou et al. [31]). All these receptors
are mainly expressed in liver and/or colon cells.
It is interesting to note that gene regulation by SXR
depends not only on the cell line but also on the SXR
activator drug. For example MDR1, which is known to
be a SXR target gene, does not exhibit any expression
change after SN-38 treatment in LS180 whereas it is
strongly induced by SXR upon rifampicin stimulation in
the same cells (data not shown). Masuyama et al.[ 3 2 ]
explain this specificity of gene induction by involvement
of transcription co-activator proteins. Depending on the
ligand, SXR would interact with different co-activators,
leading to the induction of specific genes. In addition,
Zhou et al. [33] have demonstrated that different co-
repressors could also be involved in tissue-specific gene
induction by SXR.
Surprisingly, if SN-38 is a SXR activator, CPT-11 is
not. Assuming that there is a direct binding of these
compounds on SXR, specific activation could be due to
differences in ligand affinities for the receptor. This is
surprising considering the very close structure of these
two compounds and the SXR ligand binding pocket
ability to welcome a great number of chemically differ-
ent molecules [34]. Such differences have already been
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Figure 6 Effect of SXR overexpression on LS180 and HCT116
survival after SN-38 treatment. A. Detection of carboxylesterase 2
(CE2) by western blot in LS180, HepG2 and HCT116 cells. B. and C.
LS180 cells (B) and HCT116 cells (C) were transfected with control or
SXR vector for 24 h, then treated for 72 h with different CPT-11
concentrations. The SXR overexpression was confirmed by western
blot after 24 h transfection. Cell viability following irinotecan
exposure was determined by SRB assay by comparison with
untreated cells. Each point represents the mean of 3 replicates and
the experiment has been repeated 3 times. All results are expressed
as the mean ± SE and obtained data were analysed for statistical
differences by Student’s t test. A p value of less than 0.05 was
considered statistically significant (star indicates p < 0.05).
Figure 7 Proposed model for the SXR-mediated response to
irinotecan in colon cancer cells. In LS180 cells, CPT-11 is
metabolized to SN-38 by the carboxylesterases (CE). SN-38 induces
the activation of SXR. Consequently, the transcription factor is
recruited to the CYP3A4 and CYP3A5 promoter and upregulates the
expression of these genes. SXR also constitutively activates MDR1
and MRP1 expression. As a feedback loop, CYP3A4, CYP3A5 and the
transporters reduce the concentration of active irinotecan inside the
cell, which favors cell proliferation. As a consequence, we propose
that the combined detection of SXR together with a high
expression of CYP3A4 should help to define in advance the subsets
of tumors that will fail to respond to chemotherapy based on
irinotecan treatment.
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Page 7 of 12described between paclitaxel and docetaxel [35]. The
weak impact of CPT-11 on metabolism gene induction
could be due to its requirement to be converted into its
active form SN-38 by CE2, which is expressed in HepG2
and LS180 cells. Moreover, Xu et al. [36] have evaluated
CE2 expression in different tumors and have shown that
66% of tumor tissues expressed CE2 and that conversion
of CPT-11 to SN-38 was correlated with the enzyme
expression.
Knowing that detoxification is not the only mechan-
ism involved in resistance to irinotecan, it will be inter-
esting to determine if other genes are involved in the
SXR mediated resistance. We have showed that the tar-
get gene (TOPO1) expression was not modified after
treatment (data not shown). Irinotecan resistance could
also be related to the changes of expression of DNA
repair genes, cell cycle genes, cell death and survival
pathway genes. Recently, two teams studied the anti-
apoptotic role of SXR in some cancer cell lines [37,38].
They both demonstrated that overexpressed SXR in
human cell lines protected against induced apoptosis
and promoted drug resistance in connection with the
upregulation of some anti-apoptotic genes and downre-
gulation of several pro-apoptotic genes. Nevertheless,
other studies reported a pro-apoptotic role of human
SXR in breast cancer cells [39] or in colon cancer cells
[40] but, as seen in a previous paragraph, this difference
of gene regulation can be explained respectively by cell-
type specificity and ligand specificity of SXR induction.
We have observed that SXR is involved in irinotecan
detoxification. Other studies implicating SXR in antican-
cer drug detoxification like paclitaxel, cisplatin, tamoxi-
fen or etoposide are already available [35,41-44]. Its
involvement in resistance to paclitaxel and vinblastine in
prostate cancer is clearly observed by Chen et al.[ 4 5 ] .
In addition, a recent study showed that SXR was overex-
pressed in colon cancer tissues and suggested that the
nuclear receptor may play role in resistance to 5-fluor-
ouracil and oxaliplatin, two drugs used in treatment of
colorectal cancer [46]. Those data clearly corroborate
our work by demonstrating the influence of SXR on
antineoplastic agents.
In addition, the ability of SXR to be activated by
diverse therapeutic compounds places it as a major
component in drug-drug interaction. This nuclear
receptor is induced by a wide range of drugs: the anti-
biotic rifampicin, the anticancer drugs cited above, the
barbiturate phenobarbital, the corticoid dexamethasone,
the HIV protease inhibitor ritonavir or the antidepres-
sant hyperforine [9,47-49]. Consequently, during a co-
administration, SXR activation, leading to the induction
of its target genes, could cause an accelerated metabo-
lism of one of the drugs by the CYP3A4. This could
lead to a diminution of clinical efficacy and could be at
the origin of strong resistances. For example, a drug-
drug interaction has been observed in some patients
with glioma who have received CPT-11 and dexametha-
sone [50,51]. The discovery of SN-38 as a new activator
of SXR may help prevent some cases of drug-drug inter-
action unsuspected until now. Considering that one of
the SXR target gene, CYP3A4, is alone responsible for
the metabolism of more than 50% of the drugs currently
administrated, the search of novel partners of SXR is
clearly relevant.
Conclusions
All together, these results uncover new functions for the
SXR pathway in the understanding of resistance to iri-
notecan. Our results suggest that tumors expressing
SXR might be more resistant to anticancer treatment.
We therefore propose that the SXR pathway should be
considered as a valuable tool to predict the subsets of
tumors that will fail to respond to chemotherapy.
Methods
Cell lines and treatment
LS180, HepG2 and HCT116 cells were purchased from
the ATCC (Manassas, VA, USA). Experiments were
done in MEM supplemented with 10% fetal bovine
serum (Invitrogen, Carlsbad, CA, USA). Rifampicin and
irinotecan were purchased from Sigma-Aldrich (St.
Louis, MO, USA) and SN-38 from Aventis (Bridgewater,
NJ, USA).
Nuclear and cytoplasmic and total extracts
The cell pellets were suspended in buffer A (10 mM
Hepes pH 7.9, 10 mM KCl, 1.5 mM MgCl2), kept on
ice for 15 min, then subjected to 3 freeze-thaw cycles.
The nuclei were pelleted by centrifuging at 400 g for 5
min at 4°C while supernatant was conserved as cytoplas-
mic fraction. Nuclei were washed with 1 ml buffer A,
centrifuged at 400 g for 5 min at 4°C, resuspended in
buffer C (20 mM Hepes, 420 mM KCl, 1.5 mM MgCl2,
0.2 mM EDTA, 25% glycerol) and kept on ice for 30
min. The nuclear fraction was then submitted to 10 s
pulse sonication, centrifuged at 14000 g and supernatant
were collected.
For total extract, cells were lysed in buffer C and incu-
bated for 30 min on ice. Lysates were submitted to 10 s
sonication and centrifugated at 15000 g during 5 min.
Supernatant was collected and protein concentrations
were determined by the Bradford method with Bio-Rad’s
Protein Assay Reagent (Bio-Rad, Hercules, CA) using
BSA standards (Pierce, Rockford, IL).
Western Blot
Protein extracts were loaded on 10% SDS/PAGE gels
then proteins were transferred to PVDF membranes.
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1 h, immunoblotted overnight at 4°C with anti-SXR
(Santacruz Biotechnology, Santa Cruz, CA, USA or
Abcam, Cambridge, MA, USA), anti-histone H3 (Cell
Signaling, Beverly, MA, USA), anti-a-tubulin (Sigma), or
anti-GAPDH (American Research Products, Belmont,
MA, USA), then incubated with the secondary HRP-
conjugated antibody. Bands were visualized using ECL
detection reagents (Amersham Biosciences, Pittsburgh,
PA, USA) and quantified with the ChemiDoc™ XRS
imager (Bio-Rad, Hemel Hempstead, UK).
Immunofluorescence
LS180 cells were fixed with 2% paraformaldehyde in PBS
for 30 min at room temperature then permeabilized for
30 min in 70% ethanol. After blocking with 1% BSA,
indirect immunostaining was performed using an anti-
SXR antibody (Santa Cruz Biotechnology) and a fluores-
cein isothiocyanate-conjugated secondary antibody (San-
tacruz Biotechnology). Nuclei were stained with
propidium iodide. Cells were observed using an Olym-
pus confocal microscope (Olympus, Rungis, France),
with high magnification (x630).
Cell cycle assay
LS180 cells were permeabilised and fixed with ethanol
70%, treated with RNase A for 30 min at 37°C then
incubated 5 min with propidium iodide. Cell cycle ana-
lysis was performed on a FACSort flow cytometer (BD
Biosciences, San Jose, CA, USA) and data were analysed
with Flowjow software (TreeStar, Inc., Ashland, OR,
USA).
Coimmunoprecipitation Assays
HepG2 and LS180 cells were treated with 10 μMr i f a m -
picin, 1 μg/ml CPT-11 or 10 ng/ml SN-38 for 4 h. Har-
vested cells were suspended in lysis buffer (20 mM
H e p e sp H8 ,0 . 2m ME D T A ,5 %g l y c e r o l ,1 0 0m M
NaCl, 0.1% nonidet P-40, 0.25% sodium deoxycholate, 1
mM NaF, 1 mM sodium orthovanadate, 1 mM DTT).
After 10 min incubation on ice followed by sonication
and centrifugation, cell extracts were precleared by incu-
bation for 30 min at 4°C with 20 μl protein G sepharose
- 50% slurry (Amersham). After centrifugation, mix was
incubated with 1 μg of anti-SXR or anti-RXR (Santa
Cruz Biotechnology) for overnight at 4°C. Immune com-
plexes were collected by incubation with 20 μlp r o t e i n
G sepharose for 1 h and were washed five times with
lysis buffer. CPT-11, SN-38 or rifampicin were added
during immunoprecipitation and washing steps.
Chromatin Immunoprecipitation
Cells were rinsed in PBS, cross-linked by adding formal-
dehyde (1% in PBS) for 10 min and the reaction was
stopped with 125 mM glycine for 5 min. After two
rinses, cells were scraped in lysis buffer (1% SDS, 10
mM EDTA, 50 mM Tris-HCl pH 8.1) and lysate was
subjected to sonication for four 15-second pulses and
centrifuged at 14000 g for 15 min at 4°C. The superna-
tant was diluted 2-fold in buffer (150 mM NaCl, 50 mM
Hepes pH 7.9, 1% triton-X100, 0.1% SDS, 2 mM EDTA)
and precleared by adding 2 μg of salmon sperm DNA
and 20 μl Protein G sepharose, and rotating for 1 h at
4°C. After a brief centrifugation, the supernatant was
incubated with 1 μg anti-SXR, anti-RNA polymerase II
or anti-phospho-RNA polymerase II (Abcam) overnight
at 4°C. The following day, the immune complexes were
collected by adding 20 μl Protein G sepharose and incu-
bating for 1 h at 4°C, followed by a centrifugation. The
pellet was sequentially washed with low-salt- (150 mM
NaCl, 50 mM Hepes pH 7.9, 0.1% SDS, 1% triton X-
100, 2 mM EDTA), high-salt- (500 mM NaCl, 50 mM
Hepes pH 7.9, 0.1% SDS, 1% triton X-100, 2 mM
EDTA), and LiCl- (20 mM tris pH 8.1, 1% NP-40, 1%
deoxycholate, 250 mM LiCl, 1 mM EDTA) wash buffers
and rinsed with TE buffer. The immune complexes were
eluted by 20 min incubation with 1% SDS and 0.5 M
NaHCO3. The formaldehyde-induced cross-links were
reversed by adding NaCl to a final concentration of 5
mM and incubating at 65°C for 4 h. DNA was then pur-
ified using standard phenol/chloroform method. Classi-
cal or real-time PCR were carried out with primers
amplifying control promoter region or SXR binding sites
at -169 bp and -7734 bp from the transcriptional start
site of CYP3A4 gene. Data obtained from immunopreci-
pitated samples were compared with input for classical
PCR and normalized to values obtained with the house-
keeping gene GAPDH for qPCR.
RNA extraction and RT-PCR
After 24 h treatment, total RNA was isolated from cells
by the acid guanidinium isothiocyanate-phenol-chloro-
form extraction method [52]. For reverse transcription,
1.3 μg of random hexamers (Amersham) were added to
2 μg of total RNA in a total volume of 15 μl. The mix-
ture was incubated for 5 min at 70°C and then chilled
on ice. 4 U/μl of MMLV, 4 mM dNTPs, 1X MMLV buf-
fer and 0.8 U/μl of RNasin (Invitrogen) were added and
the whole mixture (50 μl) was further incubated at 37°C
for 1 h. Real-time PCR was carried out as describe
above. PCR was realized with 5 μl of 1/20 cDNA dilu-
tion in a final volume of 10 μl. Total RNA which has
not been reverse-transcripted was amplified and used as
DNA-free RNA sample control.
Semi-quantitative PCR
Real-time PCR was carried out using the LightCycler
System (Roche Applied Science, Mannheim, Germany).
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(MWG Biotech, Huntsville, AL, USA), 5 μlo fr e c o v e r
DNA and 1X of Master Mix (Roche) in a final volume
of 10 μl. Data analysis was essentially performed using
“Fit Point Method” in the LightCycler software version
3.5.3. Relative quantification was performed using the
comparative Cycle Threshold (CT) method by Fink et al
[53]. DNA enrichment quantification or mRNA amplifi-
cation factor were calculated relative to the presence of
GAPDH gene, according to the following equation: EF =
2
-ΔΔCT where ΔΔCT = [CTpromoter region -C T GAPDH] drug
-[ C T promoter region -C T GAPDH] no treatment for ChIP
experiment, and where ΔΔCT = [CTtarget gene-
CTGAPDH] drug -[ C T target gene-C T GAPDH] no treatment for
RT-PCR experiment.
The factor was determined from the average of 3
experiments. The sequences of PCR primers are avail-
able upon request.
SXR transcription inhibition
siRNA experiments were carried out with Dharmafect
reagent (Thermo Scientific Dharmacon, Lafayette, CO,
USA) in LS180 cells, according to the manufacturer’s
protocol. Cells were transfected 48 h prior treatment
with 25 nM siRNA against SXR (SMARTpool Dharma-
con) and corresponding amount of siRNA control.
SMARTpool is a mixture of four individual siRNA.
HepG2 cells were transfected with 5 nM siRNA from
QIAgen (Hilden, Germany) using HiPerfect reagent fol-
lowing manufacturer’s instruction (Qiagen). Transfection
were performed 48 h and 24 h before treatment.
Target protein expression was controlled by western
blot 48 h after siRNA transfection, prior the 24 h drug
treatment.
SRB assay and statistical analysis
The major SXR transcript variant (SXR.1, [54]) cDNA
was isolated from human liver cDNA library (Takara
Bio Inc., Shiga, Japan) and cloned into the pcDNA3.1
vector (Invitrogen). Cells were transfected with
pcDNA3.1-SXR or pcDNA 3.1-control 24 h before treat-
ment. Then, different dilutions of CPT-11 were added to
cells and cell survival was measured after 72 h with the
sulforhodamine B assay [55]. Each point represents the
mean of 3 replicates and the experiment was repeated 3
times. All results are expressed as the mean ± SE and
data were analyzed for statistical differences by Student’s
t test. A p-value of less than 0.05 was considered statis-
tically significant.
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